肝癌患者细胞免疫状态的研究及肝癌切除对细胞免疫的影响
|
摘要
目的:
探讨肝癌患者系统性细胞免疫状态及临床意义;分析肝癌切除对细胞免疫的影响。
方法:
利用流式细胞术检测肝癌患者和健康对照组外周血T淋巴细胞亚群的频数表达;并分析肝癌切除前后外周血淋巴细胞亚群频数表达的变化;利用酶联免疫吸附实验检测肝癌患者和健康对照组外周血细胞因子的表达。同时分析肝癌T淋巴细胞亚群和细胞因子表达与肝癌生物学特征的关系。
结果:
与健康组相比,肝癌患者外周血T淋巴细胞亚群频数分布异常;T淋巴细胞分布和肝癌生物学及TNM分期相关。CD4+/CD8+比值与CD3+T细胞比例呈明显负相关;CD4+CD25+T细胞频数表达与CD4+/CD8+比值亦呈明显负相关,与CD3+CD45R0+T细胞表达呈明显正相关。Foxp3+T细胞可能下调了CD8+GranzymeB+T细胞的表达。
用CD4+CD25+Foxp3+T细胞的频数表达来反映调节性T细胞的表达状态较CD4+CD25+T细胞更为合理和科学。
肝癌患者外周血Th1/Th2型细胞因子表达失衡;细胞因子表达谱和肝癌生物学及TNM分期相关。肝癌外周IL—10表达和IFN—γ呈正相关,提示二者在作用上可能存在协同性,一定条件下IL—10可能发挥出免疫正调节作用。
肝癌切除可引起暂时性的免疫抑制加重;肝癌切除通过消减肿瘤负荷减少了肿瘤相关性调节性T细胞的表达。肝癌切除术后1月左右机体细胞免疫功能有改善倾向。
结论:
肝癌患者细胞免疫处于抑制状态,T淋巴细胞亚群表达的检测可作为评价肝癌细胞免疫状态的指标;肝细胞肝癌外周血淋巴细胞转录因子Foxp3表达的异常增加可能在肝癌细胞免疫抑制中发挥着重要作用。肝癌患者细胞免疫状态和肝癌侵袭及演进相关;
异常增加的外周调节性T细胞在肝癌较早期阶段发挥调节作用。
肝癌切除可能有助于抗肿瘤免疫的恢复;肝癌患者围手术期很可作为免疫干预的重要窗口期;调节性T细胞可作为免疫干预的靶点。
Objectives:
The present study aims to evaluate the systemic cell-mediated immunity and its clinical significance in patients with hepatocellular carcinoma.The influence of liver cancer resection on cell-mediated immunity was also analyzed.
Methods:
By flow cytometric ananlysis the presence of peripheral blood T lymphocyte subsets in HCC patients and healthy donors were evaluated. The dynamic presence of peripheral T lymphocyte subsets before and after liver cancer resection was also studied.With enzyme-linked immunosorbent assay,the serum cytokines expression of HCC patients and healthy donors were measured.The relationship between the presence of T lymphocyte subsets,cytokine expression and HCC biologic characteristics and TNM stages were analyzed.
Results:
Compared with the healthy donors,there is significantly abnormal presence of peripheral T lymphocyte subsets,which is related with the HCC biology and TNM stages.CD4+/CD8+ ratio was negatively correlated with the frequency of CD4+CD25+ regulatory T lymphocyte and CD3+T lymphocyte.There was a significant positive correlation between the frequency of CD4+CD25+ regulatory T lymphocyte and CD3+CD45RO+T lymphocyte.Foxp3 positive T lymphocyte may downregulate the expression of CD8+GranzymeB+T cells.
It is more specific and reasonable to denote regulatory T cells by CD4+CD25+Foxp3+ T lymphocytes than CD4+CD25+T lymphocytes.
There is also a Th1/Th2 serum cytokine imbalance profile in HCC patients and the imbalance is related with HCC biology.There was a significant positive correlation between the expression of peripheral interleukin-10 and interferon-gamma which may imply that interleukin -10 can function as a immunostimulative factor in some conditions and there may be a synergy between the biologic function of peripheral interleukin-10 and interferon-gamma.
Our results suggest that liver cancer resection may lead to a temporal enhancement of immunosuppression.However liver cancer resection may reduce the tumour-related regulatory T cells by abating the tumour load.There is a tendency to improve in cell-mediated immunity about one month after sugery.
Conclusions:
The cell-mediated immunity in HCC patients is in a immunosuppressive condition.The expression of peripheral T lymphocyte subpopulations could be served as the index to evaluate cellular immunity in hepatocellular carcinoma.The abnormal increase of transcription factor Foxp3 expression in peripheral lymphocyte may play an important role in regulate the immunosuppression in hepatocellular carcinoma.The immunosuppressive condition is related with the invasion and progression of HCC.
Aberrantly increased peripheral regulatory T lymphocytes may play an important role in the early stage of hepatocellular carcinoma progression.
Liver cancer resection may be helpful for the recovery of anti-tumour immunity.The perioperative period of HCC patients may be a beneficial window-phase for immune intervention and regulatory T cells may be served as a target cell.
探讨肝癌患者系统性细胞免疫状态及临床意义;分析肝癌切除对细胞免疫的影响。
方法:
利用流式细胞术检测肝癌患者和健康对照组外周血T淋巴细胞亚群的频数表达;并分析肝癌切除前后外周血淋巴细胞亚群频数表达的变化;利用酶联免疫吸附实验检测肝癌患者和健康对照组外周血细胞因子的表达。同时分析肝癌T淋巴细胞亚群和细胞因子表达与肝癌生物学特征的关系。
结果:
与健康组相比,肝癌患者外周血T淋巴细胞亚群频数分布异常;T淋巴细胞分布和肝癌生物学及TNM分期相关。CD4+/CD8+比值与CD3+T细胞比例呈明显负相关;CD4+CD25+T细胞频数表达与CD4+/CD8+比值亦呈明显负相关,与CD3+CD45R0+T细胞表达呈明显正相关。Foxp3+T细胞可能下调了CD8+GranzymeB+T细胞的表达。
用CD4+CD25+Foxp3+T细胞的频数表达来反映调节性T细胞的表达状态较CD4+CD25+T细胞更为合理和科学。
肝癌患者外周血Th1/Th2型细胞因子表达失衡;细胞因子表达谱和肝癌生物学及TNM分期相关。肝癌外周IL—10表达和IFN—γ呈正相关,提示二者在作用上可能存在协同性,一定条件下IL—10可能发挥出免疫正调节作用。
肝癌切除可引起暂时性的免疫抑制加重;肝癌切除通过消减肿瘤负荷减少了肿瘤相关性调节性T细胞的表达。肝癌切除术后1月左右机体细胞免疫功能有改善倾向。
结论:
肝癌患者细胞免疫处于抑制状态,T淋巴细胞亚群表达的检测可作为评价肝癌细胞免疫状态的指标;肝细胞肝癌外周血淋巴细胞转录因子Foxp3表达的异常增加可能在肝癌细胞免疫抑制中发挥着重要作用。肝癌患者细胞免疫状态和肝癌侵袭及演进相关;
异常增加的外周调节性T细胞在肝癌较早期阶段发挥调节作用。
肝癌切除可能有助于抗肿瘤免疫的恢复;肝癌患者围手术期很可作为免疫干预的重要窗口期;调节性T细胞可作为免疫干预的靶点。
Objectives:
The present study aims to evaluate the systemic cell-mediated immunity and its clinical significance in patients with hepatocellular carcinoma.The influence of liver cancer resection on cell-mediated immunity was also analyzed.
Methods:
By flow cytometric ananlysis the presence of peripheral blood T lymphocyte subsets in HCC patients and healthy donors were evaluated. The dynamic presence of peripheral T lymphocyte subsets before and after liver cancer resection was also studied.With enzyme-linked immunosorbent assay,the serum cytokines expression of HCC patients and healthy donors were measured.The relationship between the presence of T lymphocyte subsets,cytokine expression and HCC biologic characteristics and TNM stages were analyzed.
Results:
Compared with the healthy donors,there is significantly abnormal presence of peripheral T lymphocyte subsets,which is related with the HCC biology and TNM stages.CD4+/CD8+ ratio was negatively correlated with the frequency of CD4+CD25+ regulatory T lymphocyte and CD3+T lymphocyte.There was a significant positive correlation between the frequency of CD4+CD25+ regulatory T lymphocyte and CD3+CD45RO+T lymphocyte.Foxp3 positive T lymphocyte may downregulate the expression of CD8+GranzymeB+T cells.
It is more specific and reasonable to denote regulatory T cells by CD4+CD25+Foxp3+ T lymphocytes than CD4+CD25+T lymphocytes.
There is also a Th1/Th2 serum cytokine imbalance profile in HCC patients and the imbalance is related with HCC biology.There was a significant positive correlation between the expression of peripheral interleukin-10 and interferon-gamma which may imply that interleukin -10 can function as a immunostimulative factor in some conditions and there may be a synergy between the biologic function of peripheral interleukin-10 and interferon-gamma.
Our results suggest that liver cancer resection may lead to a temporal enhancement of immunosuppression.However liver cancer resection may reduce the tumour-related regulatory T cells by abating the tumour load.There is a tendency to improve in cell-mediated immunity about one month after sugery.
Conclusions:
The cell-mediated immunity in HCC patients is in a immunosuppressive condition.The expression of peripheral T lymphocyte subpopulations could be served as the index to evaluate cellular immunity in hepatocellular carcinoma.The abnormal increase of transcription factor Foxp3 expression in peripheral lymphocyte may play an important role in regulate the immunosuppression in hepatocellular carcinoma.The immunosuppressive condition is related with the invasion and progression of HCC.
Aberrantly increased peripheral regulatory T lymphocytes may play an important role in the early stage of hepatocellular carcinoma progression.
Liver cancer resection may be helpful for the recovery of anti-tumour immunity.The perioperative period of HCC patients may be a beneficial window-phase for immune intervention and regulatory T cells may be served as a target cell.
引文
Immunol. 2004;22:531-562.
13 Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002;107:5-9.
14 Cho Y, Miyamoto M , Kato K, et al . CD4 + and CD8 + T cells cooperate to improve prognosis of patient s wit h esophageal squamous cell carcinoma. Cancer Res , 2003 , 63 : 1555-1559.
15 Nakamura H , Kawasaki N , Hagiwara , et al . Cellular immunologic parameters related to age , gender , and stage in lung cancer patients . Lung Cancer , 2000 ,28 :139 - 145.
16 Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL- 2 and TGF- beta or IL- 10 in the generation and function of CD4 +CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol, 2003, 74(4): 471- 478.
17 Azuma T, Takahashi T, Kunisato A, et al. Human CD4+CD25+ regulatory T cells suppress NKT cell function. Cancer Res, 2003, 63: 4516- 4520.
18 Lars A. Ormandy, Tina Hillemann, Heiner Wedemeyer, et al. Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Res 2005; 65: 2457-2464.
19 Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer.2007;121:2473-2483.
20 Sasaki A, Tanaka F, Mimori K, et , al. Prognostic value of tumor-infiltrating FOXP3(+) regulatory T cells in patients with hepatocellular carcinoma.Eur J Surg Oncol. 2008;34:173-179.
21 Gao Q, Qiu SJ, Fan J, Zhou J, et, al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
22 Cai XY, Qiu SJ, Wu ZQ, et al. Relationship between dendritic cells and memory T lymphocytes in tumor site and prognosis of hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 2005;85:671-675.
23 Cao M, Cabrera R, Xu Y, et , al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4 (+)CD25 (+) regulatory T cells. Lab Invest. 2007;87:582-590.
24 Rey-Ferro M, Castano R, Orozco O, Serna A, Moreno A. Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition 1997; 13: 878-881.
25 Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-2339.
26 Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115-123.
27Sasada T, Kimura M,Yoshida Y, et al. CD4+CD25+regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 2003, 98: 1089- 1099.
28 Wolf AM, Wolf D, Steurer,et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res, 2003, 9: 606-612.
29 Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4+CD25+ regulatory cells augments the generation of specificimmune T cells in tumor- draining lymph nodes. J Immunother, 2002, 2: 207- 217.
30 Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003;19:165 - 168.
31 Wever PC, Vandervliet HJJ, Spaeny LHA, et al. The CD8 + granzyme B + T-cell subset in peripheral blood from healthy individuals contains activated and apoptosis-prone cells. Immunology 1998; 93: 383-389.
32. Sakaguchi S. Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004:22:531-562.
33. Fontenot JD, Gavin MA, Rudensky AY. FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4: 330-336.
34. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276.
35. Strauss L, Bergmann C, Szczepanski M, et, al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and trans-forming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007 ;13:4345-4354.
36 Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
37 Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
38 Unitt E, Rushbrook SM, Marshall A,et, al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005; 41: 722-730.
39 Fontenot JD, Gavin MA, Rudensky AY. FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4: 330-336.
40 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by thetranscription factor FoxP3. Science. 2003; 299: 1057-1061.
41 Khattri R, Cox T, Yasayko S-A, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003; 4: 337-342.
42 Yang XH, Yamagiwa S, IchidaT, MatsudaY,et, al. Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepato -cellular carcinoma. J Hepatol. 2006;45:254-262.
43 Zhang HH, Fei R, Mei MH, et, al.The frequency, phenotypes and functions of CD4+ CD25+ regulatory T cells in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi. 2007;15:266-272.
44 de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.
45 Romagnani S. The Thl/Th2 paradigm. Immunol Today. 1997;18:263 - 266.
46 Parker DC. T cell-dependent B cell activation. Annu Rev Immunol. 1993:11:331 -360.
47 Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19:209 - 216.
48 Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell. 2005 ;7:403-5.
49 Pellegrini P, Berghella AM, Del Beato T, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996;42:1-8.
50 Johansson M, Tan T, de Visser KE, Coussens LM. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem. 2007 ;101:918-26.
51 David G DeNardo, Lisa M Coussens Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. reast Cancer Res. 2007; 9: 212.
52 Chia CS, Ban K, Ithnin H, et al. Expression of interleukin-18, interferon-gamma and interleukin-10 in hepatocellular carcinoma. Immunol Lett. 2002:84:163-172.
53 Moss RB, Moll T, El-Kalay M, et al. Th1/Th2 cells in inflammatory disease states:therapeutic implications. Expert Opin Biol Ther 2004 ;4:1887 - 1896.
54 Aoki Y, Tsuneki I, Sasaki M, et al. Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. Gynecol Obstet Invest. 2000;50:207-211.
55 Becker Y. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Anticancer Res. 2006:26:1113-1134.
56 Yoshimoto T, Tsutsui H, Tominaga K, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA, 1999, 96: 13962-13967.
57 Nakanishi K, Yoshimoto T , Tsutsui H , et al. Interleukin - 18 regulates both Th1 and Th2 responses. Annu Rev Immunol , 2001 , 19 : 423-434.
58 Huang M , Wang J , Lee P , et al. Human non -small cell lung cancer cells express a type 2 cytokines pattern. Cancer Res ,1995 ,55 :3847 -3850.
59 Masakazu Okamoto, Yoshinori Hasegawa, Toru Hara, et al. T-Helper Type 1/T-Helper Type 2 Balance in Malignant Pleural Effusions Compared to Tuberculous Pleural Effusions* Chest. 2005;128:4030-4035.
60 Nakayama H, Kitayama J, Muto T, et al. Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn J Clin Oncol. 2000;30:301-305.
61 Dokka, S., Shi, X., Leonard, S.,et al. Interleukin-10-mediated inhibition of free radical generation in macrophages Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280, L1196-L1202.
62 Marra, L. E., Zhang, Z. X., Joe, B., et al. IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-α . J Immunol. 2004, 172,1028-1035。
63 Lauw, F. N., Pajkrt, D., Hack, C. E., et al. Proinflammatory effects of IL-10 during human endotoxemia J. Immunol. 2000, 165: 2783-1789.
64 Malaguarnera L, Motta M, Di Rosa M, Anzaldi M, Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer' s disease and vascular dementia. Neuropathology. 2006;26:307-312.
65 Ercolani G, Grazi GL, Ravaioli M,et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003:237:536-43.
66 Tangkijvanich P, Thong-Ngam D, Mahachai V, et al. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol. 2007; 28;13:4345-4349.
67 Asakawa M, Kono H, Amemiya H, et al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer. 2006;118:564-570.
68 Mojtahedi Z.Interleukin (IL)-18 may enhance Th1 response in early cancer but aggravate malignant disease in its later stages. Med Hypotheses. 2005:65:995-996.
69 Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-5592.
70 Whelan RL. Laparotomy, laparoscopy, cancer, and beyond. Surg Endosc. 2001:15:110-115.
71 Whelan RL, Franklin M, Holubar SD, et al. Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans. Surg Endosc. 2003;17:972-978.
72 Hofer SO, et, al the effect of surgical wounding on tumor development. Eur J Surg Oncol 1999,25:231-243.
73 Whelan RL, Allendorf JD, Gutt CN, et al. General oncologic effects of the laparoscopic surgical approach.1997 Frankfurt international meeting of animal laparoscopic researchers.Surg Endosc.1998;12:1092-1095.
74 Carter JJ,Whelan RL.The immunologic consequences of laparoscopy in oncology.Surg Oncol Clin N Am.2001;10:655-677.
75 Beyer M,Schultze JL.Regulatory T cells in cancer.Blood 2006;108:804-811.
76 Sylla P,Kirman I,Whelan RL.Immunological advantages of advanced laparoscopy.Surg Clin North Am.2005:85:1-18.
77 Takagi K,Yamamori H,Morishima Y,et al.Preoperative immunosupp ression:its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy.Nutrition,2001,17:13-17.
78 Leaver HA,Craig SR,Yap PL,et al.Lymphocyte responses following open and minimally invasive thoracic surgery.Eur J Clin Invest,2000,30:230-238.
79 Hiraki S,Ono S,Kinoshita M,Interleukin-18 restores immune suppression in patients with nonseptic surgery,but not with sepsis.Am J Surg.2007;193:676-680.
80 Ajima K et,al Detection of T cell apoptosis after major operations.Eur J Surg 1999,165:1020-1023.
81 Ogawa K,Hirai M,Katsube T,et al.Suppression of cellular immunity by surgical stress.Surgery.2000;127:329-336.
82 彭聿平,邱一华.手术应激与免疫抑制生理科学进展2006,37:31-36.
83 Matsuda A,Furukawa K,Suzuki H,et al.Does impaired TH1/TH2 balance cause postoperative infectious complications in colorectal cancer surgery? J Surg Res.2007;139:15-21.
84 Budhu A,Forgues M,Ye QH,et al.Prediction of venous metastases,recurrence,and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.Cancer Cell.2006;10:99-111.
85 邢雪,吴在德.肝癌患者免疫功能的临床研究.中华实验外科杂志1996,13:333-334.
86 Hussein MR,Hassan HI,Hofny ER,et al.Alterations of mononuclear inflammatory cells,CD4/CD8+ T cells,interleukin lbeta,and tumour necrosis factor alpha in the bronchoalveolar lavage fluid,peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol. 2005:58:178-184.
87 Markowska J, Lacki JK, Jaroszewski J, et al.The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients. Eur J Gynaecol Oncol. 1995:16:54-58.
88 Ohara T, Takahashi M, Yamanaka H, et al.Serum lactate dehydrogenase and CD4+/CD8+ lymphocyte ratio predict survival in terminally ill cancer patients. Gan To Kagaku Ryoho. 2002:29:1779-1783.
89 Sevcikova L, Hundkovd L, Chorvdth B, et al.T-lymphocyte subsets (CD4/CD8 ratio) in breast cancer patients. Neoplasma. 1992:39:219-222.
90 Mascitelli L, Pezzetta F. Regulatory T cells, allergic diseases, and cancer. Chest. 2008 ;133:832.
91 Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008:83:523-535.
92 Peng L, Kjaergaard J, Plautz GE, et al. Tumor induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002:169:4811-4821.
93 Van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases. Ann N Y Acad Sci 2007:1113:217-237.
94 Ni Choileain N, MacConmara M, Zang Y, et al. Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol. 2006:176:225-236.
95 Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005:115:3623-3633.
1 Sakaguchi S.Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses.Annu Rev Immunol 2004;22:531-562.
2 Emma J,Michaela DV,Denise G,et al.CD25 - regulatory Tcells and tumor immunity.Immunology Letters 2003;85:141-143.
3 Maloy K,Powrie F.Regulatory T cells in the control of immune pathology.Nature Immunol,2001,2:816.
4 Kubach J,Lutter P,Bopp T,et al.Human CD4+CD25+ regulatory T cells:proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function.Blood.2007;110:1550-1558.
5 Dieckmann D, Plottner H, Berchtold S Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001:193:1303-1310.
6 Goleva E, Cardona ID, Ou LS, et al. Factors that regulate naturally occurring T regulatory cell2mediated supp ression. J Allergy Clin Immunol, 2005, 116: 1094-1100.
7 Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003;171:6323-6327.
8 Jordan MS, Boesteanu A, Reed AJ et al: Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001:2:301-306.
9 Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med. 2004:199:1401-1408.
10 Tarbell KV, Yamazaki S, Steinman RM. The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity. Semin Immunol, 2006, 18: 93 - 102.
11 Bacchetta R, Gregori S, RoncaroloMG. CD4 + regulatory Tcells: mechanisms of induction and effector function. Autoimmun Rev, 2005, 4: 491-496.
12 Mahnke K, Enk AH. Dendritic cells: key cells for the induction of regulatory T cells? Curr Top Microbiol Immunol, 2005, 293: 133-150.
13 Nelson BH: IL-2, regulatory T cells, and tolerance. J Immunol. 2004 ,172:3983-3988.
14 Takahashi T, Tagami T, Yamazaki S et al. Immunologic self -tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte- associated antigen 4. J Exp Med. 2000:192:303-310.
15 Ronchetti S, Zollo O, Bruscoli S, et al. Frontline: GITR, a member of the TNF receptor superfamily, is co-stimulatory to mouse T lymphocyte subpopulations. Eur J Immunol, 2004,34:613-622.
16 Zheng SG, MengLZ, Wang JH, et al. Transfer of regulatoryT cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4 + CD25 + cells in the recip ient. Int Immunol, 2006, 18: 279-289.
17 Becker C, FantiniMC, NeurathMF. TGF-beta as a T cellregulator in colitis and colon cancer. Cytokine Growth FactorRev, 2006, 17: 97 - 106.
18 Schramm C, Huber S, Protschka M, et al. TGF- β regulates the CD4 + CD25 + T cell pool and the exp ression of Foxp3 in vivo. Int Immunol, 2004, 16: 1241-1249.
19 Fontenot JD, GavinMA, Rudensky A Y. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol, 2003; 4: 330 - 336.
20 Khattri R, Cox T, Yasayko S, et a l. An essential role for Scurfin in CD4 + CD25 + T regulatory cells. Nat Immunol, 2003; 4: 337 -342.
21 Yagi H, N omura T, N akamura K, et a 1. C rucial role of FOXP3 in the development and function of human CD25 + CD4 + regulatory T cells. Int Immunol, 2004; 16: 1643 - 1656.
22 RoncaroloMG, L evings M K. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol, 2000; 12: 676 - 683.
23 Lan YY, Wang Z, Raimondi G, et al. Alternatively activateddendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol. 2006;177:5868-5877.
24 Coffer PJ , Burgering BM. Forkhead box transcrip tion factors and their role in the immune system. Nat Rev Immunol, 2004, 4: 889-899.
25 FantiniMC, Becker C, Monteleone C, et al. TGF-beta induces a regulatory phenotype in CD4 + CD25 + T cellsthrough Foxp3 induction and down-regulation of Smad7. JImmunol, 2004, 172: 5149-5153.
26 Gelman AE et al Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172:6065-6073.
27 Caramalho, I. et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp Med. 2003, 197: 403-411.
28 Peng G. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science. 2005; 26:1380-1384.
29 YipingYang et al Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nature immunology 2004,5:508-515.
30 Shevach E M. CD4 + CD25 + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
31 LevingsM K, Bacchetta R, Schulz U et al. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263-276.
32 Misra N, Bayry J, Lacroix Desmazes S, et al. Cutting edge: human CD4 + CD25 + T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172 : 4676-4680.
33 Stassen M, Schmitt E, Jonuleit H. Human CD4 + CD25+regulatory T cells and infectious tolerance. Transp lantation 2004, 77: S23-25.
34 akaguchi S. The origin of F0XP3-expressing CD4+ regulatory T cells:thymus or periphery. J Clin Invest. 2003 112:1310-1312.
35 Cederbom L, Hall H, Ivars F: CD4+CD25+ regulatory T cells down-regulatecostimulatory molecules on antigen- presenting cells. Eur J Immunol. 2000;30:1538-1543.
36 Fantini MC, Becker C, Tubbe I, et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006,55:671-680.
37 Huang X, Zhu J, Yang Y. Protection against autoimmunity in nonlymphopenic hosts by CD4+ CD25+ regulatory T cells is antigen-specific and requires IL-10 and TGF-beta. J Immunol. 2005 ,175:4283-4291.
38 Zwar TD, Read S, van Driel IR, et al. CD4 + CD25 + regulatory T cells inhibit the antigen-dependent expansion of self-reactive T cells in vivo. J Immunol 2006, 176: 1609-1617.
39 Barthlott T, Kassiotis G, StockingerB. T cell regulation as aside effect of homeostasis and competition. J Exp Med 2003, 197: 451-460.
40 Larmonier N, Marron M, Zeng Y, Tumor-derived CD4(+)CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 2007;56:48-59.
1 陈慰峰主编.医学免疫学.第四版.北京:人民卫生出版社,2004,226-227.
2 Shevde LA,et,al.Studies on functional status of circulating lymphocytes in unaffected members from cancer families.Human Immunol 1998;59:373-381.
3 Reuben JM,Hersh EM.Delayed hypersensitivity responses of cancer patients to recall antigens using a new multitest applicator.Ann Allergy 1984;53:390-394.
4 Almand B Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001:166:678-689.
5. Tomer, Y., et, al. Autoantibodies, autoimmunity and cancer. Oncol. Rep. 1998, 5: 753-761
6 Finch, C. E., Crimmins, E. M. Inflammatory exposure and historical changes in human life-spans. Science 2004, 305: 1736-1739.
7 Dannenberg, A. & Subbaramaiah. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 2003, 4: 431-436.
8 Enzler, T. et al. Deficiencies of GM-CSF and interferon link inflammation and cancer. J. Exp. Med. 2003, 197: 1213 - 1219.
9. Hoebe, K., Janssen, E. & Beutler, B. The interfacebetween innate and adaptive immunity. Nature Immunol. 2004, 5: 971-974.
10. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423: 356-361.
11. Schmielau, J et, al. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001, 61: 4756-4760.
12 Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 2005, 5,: 263 - 274.
13 Balkwill, F, et, al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 2005, 7: 211 -217.
14 Esposito, I. et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 2004,57:630-636.
15 Egeblad, M. &Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2002,2:161-174.
16 Zha, S., et, al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004,215: 1-20.
17 Pikarsky, E. et al. NF- B functions as a tumour promoter in inflammation - associated cancer. Nature 2004, 431: 461-466 .
18 Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Nature Med.2004,10:942-994.
19 Rosenberg,S.A.,et,al.Cancer immunotherapy:moving beyond current vaccines.Nature Med.2004,10:909-915.
20 Smytb,M.J.et,al.NKT cells and tumor immunity-a double-edged sword.Nature Immunol.2000,1:459-460.
21 Firestein,G.S.Evolving concepts of rheumatoid arthritis.Nature 2003,423:356-361.
22 Hoebe,K.,et,al.The interface between innate and adaptive immunity.Nature Immunol.2004,5:971-974.
23 Tan,E.M.et,al.Relative paradigms betweenautoantibodies in lupus and autoantibodies in cancer.Clin.Exp.Immunol.2003,134:169-177.
24 De Visser,K.E.,Korets,L.V.& Coussens,L.M.De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.Cancer Cell 2005,7:411-423.
25 Mueller,M.M.,Fusenig,N.E.Friends or foes-bipolar effects of the tumor stroma in cancer.Nat.Rev.Cancer,2004;4:839-849.
26 Pollard,J.W.Tumor-educated macrophages promote tumor progression and metasta-sis.Nat.Rev.Cancer 2004;4:71-78.
27 Budhu,A.,et,al.Predictionof venous metastases,recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.Cancer Cell 2006,10:99-111.
28 Duan XZ,et,al Decreased frequency and function of circulating plasmocytoid dendritic cells(pDC) in hepatitis B virus infected humans.J Clin Immunol.2004;24:637-646
29 Wang FS,et,al Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infectionWorld J Gastroenterol.2001;7:537-541.
30 Genel F,et,al.Decreased ratio of CD4/CD8 lymphocytes might be predictive for successful interferon alpha and lamivudine combined therapy in childhood chronic hepatitis B infection:A preliminary studyJ Gastroenterol Hepatol.2003;18:645-650.
31 何东苟,陈柏铭,林勇平.病毒性肝炎患者两类免疫效应细胞的功能变化临床肝胆病杂志2000,16:30-31.
32 Stoop JN,et,al Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.Hepatology.2005;;41;:771-778.
33 Falasca K,et,al.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C Ann Clin Lab Sci.2006;36:144-50
34 杨朝晖,高峰,张培会等.重型肝炎内毒素与细胞因子及细胞免疫的相关性实用医药杂志2006,23:516-19.
35 Ayada M,et,al.Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection.Hepatol Res.2006;34:214-221.
36 Yu,F.L.,et,al.Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3.J.Hepatol,2005,42:520 - 527.
37 Song,l.H.,et,al.Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus.J.Clin.Virol.2003;28:93-103.
38 Carretero,M.,et,al.The hepatitis B virus X protein binds to and activates the NH(2)-terminal trans-activation domain of nuclear factor of activated T cells-1.Virology,2002,299:288-300.
39 Akpolat N,et,al Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B.World J Gastroenterol.2005;11:3260-3263.
40 李嘉,朱理珉,梁树人等.乙型肝炎病毒核心区基因变异与细胞免疫中华肝脏病杂志2003,11:533-535.
41 王静艳,穆桂玲,刘沛等.乙型重型肝炎基因变异与免疫异常的关系中华传染病杂志2001,19:73-76.
42 冯志杰,任锡玲,牛然明.肝炎后肝硬变肝损害与细胞免疫功能新消化病学杂志1997:5:88-89.
43 Bahr MJ,Function of the immune system in liver cirrhosis Z Gastroenterol.2001;39:601-607.
44 Attallah AM,et,al.Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.Clin Exp Med.2003;3:181-185.
45 Morita K,et,al.Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease.Hepatogastroenterology.2005;52:1803-1808.
46 黄团新,周永兴,韩秀珍.肝炎肝硬化及原发性肝癌患者外周血T淋巴细胞亚群分析临床内科杂志,2001,18:69-70
47 伍艳玲,綦盛麟,石铭.肝硬化病人外周血T淋巴细胞亚群及HBV-DNA含量的变化分析大连医科大学学报2005,27:301-302.
48 Akbar,S.M.,et,al.Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis;relevance to pathogenesis.Cancer heft.2001,171:125-132.
49 Kim,Y.J.,et,al.Association of transforming growthfactor-1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.Exp.Mol.Med.2003,35:196-202.
50 周伏喜,卢放根,伍汉文等.急性肝炎、肝硬化患者血清一氧化氮与免疫细胞因子的关系湖南医科大学学报1999,24:379-380.
51 Masini E,et,al Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosisInt.Arch Allergy Immunol.1995107:197-198.
52 Giron-Gonzalez JA,et,al Implication of inflammation-related cytokines in the natural history of liver cirrhosishiver Int.2004;24:437-445.
53 Giron-GonzalezJA,et,al Adhesion molecules as a prognostic marker of liver cirrhosis。Scand J Gastroenterol.2005;40:217-224.
54 Lin SY,et,al Increased serum leptin concentrations correlate with soluble tumour necrosis factor receptor levels in patients with cirrhosis.Clin Endocrinol.2002,57:805-811.
55 Nakamoto,Y.,Guidotti,L.G.,Kuhlen,C.V.,Fowler,P.,Chisari,F.V.Immune pathogenesis of hepatocellular carcinoma.J.Exp.Med.1998,188:341-350.
56 Nakamura,I.,Imawari,M.Cellular immune response in HCV infection.J.G -astroenterol.2000,35:881-889.
57 Rehermann,B.Immune responses in hepatitis B virus infection.Semin.Liver Dis.2003,23:21-38
58 Soresi Met al Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.World J Gastroenterol.2006,12:2563-2568.
59 Yuen,M.F.,et,al.Transforming growth factor-_1,activin and follistatin in patientswith hepatocellular carcinoma and patients with alcoholic cirrhosis.Scand.J.Gastroenterol.2002,37:233-238.
60 Hu,R.H.,et,al.Secretion of acute-phase proteins before and after hepatocellular carcinoma resection.J.Formos.Med.Assoc.1999,98:85-91.
61 Tangki jvanich,et,al.Serum interleukin-6 and interferon levels in patients with hepatitis B-associated chronic liver disease.Asian Pac.J.Allergy Immunol.2000,18:109- 114.
62 Hattori E,et,al.Possible contribution of circulating interleukin-10(IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma.Hepatol Res.2003;27(4):309-314.
63 Okumoto K,et,al.Possible contribution of circulating transforming growth factor-betal to immunity and prognosis in unresectable hepatocellular carcinoma.Liver Int.2004;24:21-28.
64 Chen S,et al.Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma:relevance to hepato- carcinogenesis.Cancer Lett.2000;148:49-57.
65 Grolleau A,et,al.Dendritic cell-based vaccines for cancer therapy.Cancer Treat Res.2005;123:181-205
66 Lars A,et,al.Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.Cancer research 2005,65:2457-2464.
67 Maecker HL,Yun Z,Maecker HT,et al.Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.Cancer Cell.2002;2:139-148.
68 Hahne M,Rimoldi D,Schroter P,et al.Melanoma cell expression of Fas ligand:implications for tumor immune escape.Science 1996,274:1363-1366.
69 张建国,徐高四,李伟等.肝癌细胞Fas-FasL途径反击免疫细胞.细胞生物学杂志2008,30:100-104.
70 Yuen MF,et,al.Expression of Fas antigen(CD95) in peripheral blood lymphocytes and in liver-infiltrating,cytotoxic lymphocytes in patients with hepatocellular carcinoma.Cancer.2001;92:2136-2141.
71 Tang TJ Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol. 2006:37:332-338
72 Yin XY, et, al. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology. 2003:50:1281-1284.
73 Cai XY et , al Dendritic cell infiltration and prognosis of human hepatocellular carcinomaJ Cancer Res Clin Oncol. 2006:132:293-301
74 Unitt E, et, al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005:41:722-730.
75 Xiu Hua Yang et, al. Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. Journal of Hepatology 2006, 45:254-262.
76 Unitt E, et,al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006:45:246-253.
77 Yuen MF, et, al Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infil -trating lymphocytes in patients with primary hepatocellular carcinoma. Clin Immunol. 2001:101:264-269.
78 Ponte, M, et, al. Cytokine induced expression of killer inhibitory receptors in human T lymphocytes. Eur. Cytokine Netw. 1998, 9: 69 - 72,
79 Kakumu, S et, al, Serum levels ofIL-10, IL-15 and soluble tumor necrosis factor-a (TNF-a) receptors in type C chronic liver disease. Clin. Exp. Immunol. 1997, 109: 458-463,.
80 Iwamoto A, et, al. Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori. 2006 ; 92:130-3
81 Ikeguchi M, et, al Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas.. Onkologie. 2005 ; 28:255-9.
82 Anuradha Budhu, et, al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006 ; 10; :99-111.
83 Heneghan, M. A., et, al. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int. J. Gastrointest. Cancer 2003, 34: 19-26.
84 Kroeger, K. M., Carville, K. S., Abraham, L. J. The -308 tumor necrosis factor-promoter polymorphism effects transcription. Mol. Immunol. 1997, 34, 391-399.
85 Hirankarn, N., et, al. Interleukin-1 gene polymorphism associated with hepa- tocellular carcinoma in hepatitis B virus infection. World J. Gastroenterol. 2006, 12: 776-779.
86 Cornell RP etal. Acute phase response after acute liver injury by partial hepatectomy in rats as indicators of cytokine release Hepatology 1990,11:923-931.
87 Milland J et al Gene expressioin in regeneratin and acute-phase rat liver . Am J Physiol , 1990, 259: 340-347
88 Gupta A et, al Effect of laparoscopy on immune function. Br J Surg 2001,88:1296-1306
89 From Bical OM etal Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery. Eur J Cardiothorac Surg. 2006:29:699-702
90 Burpee SE et al The metabolic and immune response to laparoscopic vs open liver resection. Surg Endosc 2002, 16:899-904
91 Schietroma M et, al changes in the blood coagulation, fibrinolysis, and cytokine profile during laparoscopic and open cholecystectomy. Surg Endosc, 2004, 18:1090-1096
92 Halevy A et al Comparison of the serum C-reactive protein concentration for laparoscopic versus open cholecystectomy. Surg Endosc, 1995,9:280-282
93 Kaminska et al CRP, TNF , IL-1ra, IL-6, IL-8 and IL-10 in Blood Serum of Colorectal Cancer Patients Pathology Oncology Research 2000, 6: 38-41
94 Hu X et al Evaluation of the minimal invasiveness of laparoscopic operation for colorectal carcinoma Zhonghua Wei Chang Wai Ke Za Zhi. 2005 , 8:404-6
95 Weber DM Laparoscopic surgery:an excellent approach in elderly patients. Arch Surg 2003,138:1083-1088
96 Lacy AM et, al Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomized trial. Lancet 2002,359:2224-2229.
97 VittimbergaFJ et al Laparoscopic surgery and the systemic immune response. Ann surg 1998,227:326-324
98 Weitz J, et, al Surgical stress and minimal residual disease detection. Semin Surg Oncol 2001,20:329-333
99 Holmgren L , et , al Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995,1:149-153
100 Li TS, et, al The influence of tumour resection on angiostatin levels and tumour growth-an experimental study in tumour-bearing mice. European J of cancer 2001,37:2283-2288
101 Hofer SO, et, al the effect of surgical wounding on tumor development. Eur J Surg Oncol 1999,25:231-243.
102 Takagi K, Yamamori H, Morishima Y, et al. Preoperative immunosupp ression: its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy. Nutrition, 2001, 17: 13 - 17.
103 Leaver HA, Craig SR, Yap PL, et al. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest, 2000, 30: 230-238.
104 Ajima K et, al Detection of T cell apoptosis after major operations. Eur J Surg 1999,165:1020-1023.
105 Ogawa K, Hirai M, Katsube T, et al. Suppression of cellular immunity by surgical stress. Surgery 2000,127:329-336.
106 彭聿平,邱一华．手术应激与免疫抑制．生理科学进展 2006,37：31-36．
107 Atanackovic D et, al Acute psychological stress alerts the adaptive immune response: Stress-induced mobilization of effector T cells. J Neuroimmunol. 2006:176:141-52
108 Atanackovic D et, al Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes Am J Physiol Regul Integr Comp Physiol. 2006 , 290:585-594
109 邢雪,吴在德．肝癌患者免疫功能的临床研究．中华实验外科杂志、．1996,13：333-334．
110 Itoh, Y., et, al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver, 1999 19: 97 - 103.
111 Hironori Kaneko, et al Laparoscopic liver resection of hepatocellular carcinoma. The American Journal of Surgery 2005,189 :190 -194
112 Ishikawa M et, al Clarification of risk factors for hepatectomy in patients with hepatocellular carcinoma Hepatogastroenterology. 2002, ;49:1625-31.
113 Chijiiwa K Serum interleukin-6 and hepatocyte growth factor levels in patients after hepatectomy. Hepatogastroenterology. 2002 , 49:467-471.
114 Kimura F, Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection J Surg Res. 2006, 133:102-112.
115 Sato, T., et , al. Changes in tumor necrosis factor-a and interleukin-1beta production following liver surgery on cirrhotic patients. Hepatogastroenterology 1996,43: 1148-1153.
116 Calvin SH et, al Is minimal access surgery for cancer associated with immunologic benefits? World J Surg 2005, 29: 975-981.
117 Reichner, J. S., et, al. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann. Surg. Oncol. 1998, 5: 279-286.
118 Wagner, K., et, al. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology, 2004,126: 1828-1843.
119 Kubo F, et, al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005:12:800-807
120 Hira, E., et, al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radicalresection for hepatocellular carcinoma. Cancer 2005 , 103 : 588 - 598.
121 Wang, L ,et, al. Mechanism of interferon_ on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 2003, 7: 587 - 594.
122 Nagao, M., et, al. The impact of interferon _ receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology, 2000 32: 491 - 500.
123 Akiba, J., et, al. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int. J. Oncol. 2001, 18, 257-264.
124 Asakawa M, et, al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer. 2006:118:564-570
125 Gelman AE et al Toll-like receptor ligands directly promote activated CD4+ T cell survival J Immunol. 2004;172:6065-6073
126 Peng G Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science. 2005 , 26 ;309:1380-1384
127 YipingYang et al Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nature immunology 2004,5:508-515
128 Cerwenka A et al NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer Tissue Antigens. 2003 , 61:335-343
129 Holdenrieder S. Soluble MICA in malignant diseases. Int J Cancer. 2006, 118:684-687
130Liyanage UK, et al. Prevalence of regulatory T-cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-2761.
131 Curiel TJ, et al. Specific recruitment of regulatory T-cells in ovarian carcinoma fosters im -mune privilege and predicts reduced survival. Nat Med 2004;10:942 - 9.
132 Viguier M, et al. Foxp3 expressing CD4(+) CD25(high) regulatory T cells are over represent -ed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
133 Wang RF. Functional control of regulatory T cells and cancer immunotherapy Semin Cancer Biol. 2006 16:106-114
134 Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004:22:531-562.
135 Wang RF Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol. 2006, 16:73-79.
136 Wang HY, et al . Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T-cells. J Immunol 2005 ; 174:2661-2670.
137 Chen W, et al. Conversion of peripheral CD4+ CD 25- naive T-cells to CD4+CD25+ regulatory T-cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875 - 1886.
138 Apostolou I, et al In vivo instruction of suppressor commitment in naive T-cells. J Exp Med 2004;199:1401 - 1408.
139 Paul A. Antony, et, al. Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. J Immunol. 2006; 176: 5255-5266.
140 Fontenot JD, et, al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 200 5;6:1142 - 1151.
141 Kreher C R , Dittrich M T , et al. CD4 + and CD8 + cells in cryopreserved human PBMC maintain full functionality in cytokine EL ISPOT assays . Journal of Immunological Methods , 2003 ,278 :79-93.
13 Gallimore A, Sakaguchi S. Regulation of tumour immunity by CD25+ T cells. Immunology 2002;107:5-9.
14 Cho Y, Miyamoto M , Kato K, et al . CD4 + and CD8 + T cells cooperate to improve prognosis of patient s wit h esophageal squamous cell carcinoma. Cancer Res , 2003 , 63 : 1555-1559.
15 Nakamura H , Kawasaki N , Hagiwara , et al . Cellular immunologic parameters related to age , gender , and stage in lung cancer patients . Lung Cancer , 2000 ,28 :139 - 145.
16 Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL- 2 and TGF- beta or IL- 10 in the generation and function of CD4 +CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol, 2003, 74(4): 471- 478.
17 Azuma T, Takahashi T, Kunisato A, et al. Human CD4+CD25+ regulatory T cells suppress NKT cell function. Cancer Res, 2003, 63: 4516- 4520.
18 Lars A. Ormandy, Tina Hillemann, Heiner Wedemeyer, et al. Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular Carcinoma. Cancer Res 2005; 65: 2457-2464.
19 Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer.2007;121:2473-2483.
20 Sasaki A, Tanaka F, Mimori K, et , al. Prognostic value of tumor-infiltrating FOXP3(+) regulatory T cells in patients with hepatocellular carcinoma.Eur J Surg Oncol. 2008;34:173-179.
21 Gao Q, Qiu SJ, Fan J, Zhou J, et, al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
22 Cai XY, Qiu SJ, Wu ZQ, et al. Relationship between dendritic cells and memory T lymphocytes in tumor site and prognosis of hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi. 2005;85:671-675.
23 Cao M, Cabrera R, Xu Y, et , al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4 (+)CD25 (+) regulatory T cells. Lab Invest. 2007;87:582-590.
24 Rey-Ferro M, Castano R, Orozco O, Serna A, Moreno A. Nutritional and immunologic evaluation of patients with gastric cancer before and after surgery. Nutrition 1997; 13: 878-881.
25 Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 2007;132:2328-2339.
26 Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16:115-123.
27Sasada T, Kimura M,Yoshida Y, et al. CD4+CD25+regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 2003, 98: 1089- 1099.
28 Wolf AM, Wolf D, Steurer,et al. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res, 2003, 9: 606-612.
29 Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4+CD25+ regulatory cells augments the generation of specificimmune T cells in tumor- draining lymph nodes. J Immunother, 2002, 2: 207- 217.
30 Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 2003;19:165 - 168.
31 Wever PC, Vandervliet HJJ, Spaeny LHA, et al. The CD8 + granzyme B + T-cell subset in peripheral blood from healthy individuals contains activated and apoptosis-prone cells. Immunology 1998; 93: 383-389.
32. Sakaguchi S. Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004:22:531-562.
33. Fontenot JD, Gavin MA, Rudensky AY. FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4: 330-336.
34. Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-4276.
35. Strauss L, Bergmann C, Szczepanski M, et, al. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and trans-forming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007 ;13:4345-4354.
36 Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
37 Jones E, Dahm-Vicker M, Simon AK, et al. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immun 2002;2:1.
38 Unitt E, Rushbrook SM, Marshall A,et, al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005; 41: 722-730.
39 Fontenot JD, Gavin MA, Rudensky AY. FoxP3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4: 330-336.
40 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by thetranscription factor FoxP3. Science. 2003; 299: 1057-1061.
41 Khattri R, Cox T, Yasayko S-A, et al. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003; 4: 337-342.
42 Yang XH, Yamagiwa S, IchidaT, MatsudaY,et, al. Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepato -cellular carcinoma. J Hepatol. 2006;45:254-262.
43 Zhang HH, Fei R, Mei MH, et, al.The frequency, phenotypes and functions of CD4+ CD25+ regulatory T cells in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi. 2007;15:266-272.
44 de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24-37.
45 Romagnani S. The Thl/Th2 paradigm. Immunol Today. 1997;18:263 - 266.
46 Parker DC. T cell-dependent B cell activation. Annu Rev Immunol. 1993:11:331 -360.
47 Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol. 2007;19:209 - 216.
48 Houghton AN, Uchi H, Wolchok JD. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell. 2005 ;7:403-5.
49 Pellegrini P, Berghella AM, Del Beato T, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother. 1996;42:1-8.
50 Johansson M, Tan T, de Visser KE, Coussens LM. Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem. 2007 ;101:918-26.
51 David G DeNardo, Lisa M Coussens Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. reast Cancer Res. 2007; 9: 212.
52 Chia CS, Ban K, Ithnin H, et al. Expression of interleukin-18, interferon-gamma and interleukin-10 in hepatocellular carcinoma. Immunol Lett. 2002:84:163-172.
53 Moss RB, Moll T, El-Kalay M, et al. Th1/Th2 cells in inflammatory disease states:therapeutic implications. Expert Opin Biol Ther 2004 ;4:1887 - 1896.
54 Aoki Y, Tsuneki I, Sasaki M, et al. Analysis of TH1 and TH2 cells by intracellular cytokine detection with flow cytometry in patients with ovarian cancer. Gynecol Obstet Invest. 2000;50:207-211.
55 Becker Y. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Anticancer Res. 2006:26:1113-1134.
56 Yoshimoto T, Tsutsui H, Tominaga K, et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci USA, 1999, 96: 13962-13967.
57 Nakanishi K, Yoshimoto T , Tsutsui H , et al. Interleukin - 18 regulates both Th1 and Th2 responses. Annu Rev Immunol , 2001 , 19 : 423-434.
58 Huang M , Wang J , Lee P , et al. Human non -small cell lung cancer cells express a type 2 cytokines pattern. Cancer Res ,1995 ,55 :3847 -3850.
59 Masakazu Okamoto, Yoshinori Hasegawa, Toru Hara, et al. T-Helper Type 1/T-Helper Type 2 Balance in Malignant Pleural Effusions Compared to Tuberculous Pleural Effusions* Chest. 2005;128:4030-4035.
60 Nakayama H, Kitayama J, Muto T, et al. Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer. Jpn J Clin Oncol. 2000;30:301-305.
61 Dokka, S., Shi, X., Leonard, S.,et al. Interleukin-10-mediated inhibition of free radical generation in macrophages Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280, L1196-L1202.
62 Marra, L. E., Zhang, Z. X., Joe, B., et al. IL-10 induces regulatory T cell apoptosis by up-regulation of the membrane form of TNF-α . J Immunol. 2004, 172,1028-1035。
63 Lauw, F. N., Pajkrt, D., Hack, C. E., et al. Proinflammatory effects of IL-10 during human endotoxemia J. Immunol. 2000, 165: 2783-1789.
64 Malaguarnera L, Motta M, Di Rosa M, Anzaldi M, Interleukin-18 and transforming growth factor-beta 1 plasma levels in Alzheimer' s disease and vascular dementia. Neuropathology. 2006;26:307-312.
65 Ercolani G, Grazi GL, Ravaioli M,et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003:237:536-43.
66 Tangkijvanich P, Thong-Ngam D, Mahachai V, et al. Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol. 2007; 28;13:4345-4349.
67 Asakawa M, Kono H, Amemiya H, et al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer. 2006;118:564-570.
68 Mojtahedi Z.Interleukin (IL)-18 may enhance Th1 response in early cancer but aggravate malignant disease in its later stages. Med Hypotheses. 2005:65:995-996.
69 Parton M, Gore M, Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-5592.
70 Whelan RL. Laparotomy, laparoscopy, cancer, and beyond. Surg Endosc. 2001:15:110-115.
71 Whelan RL, Franklin M, Holubar SD, et al. Postoperative cell mediated immune response is better preserved after laparoscopic vs open colorectal resection in humans. Surg Endosc. 2003;17:972-978.
72 Hofer SO, et, al the effect of surgical wounding on tumor development. Eur J Surg Oncol 1999,25:231-243.
73 Whelan RL, Allendorf JD, Gutt CN, et al. General oncologic effects of the laparoscopic surgical approach.1997 Frankfurt international meeting of animal laparoscopic researchers.Surg Endosc.1998;12:1092-1095.
74 Carter JJ,Whelan RL.The immunologic consequences of laparoscopy in oncology.Surg Oncol Clin N Am.2001;10:655-677.
75 Beyer M,Schultze JL.Regulatory T cells in cancer.Blood 2006;108:804-811.
76 Sylla P,Kirman I,Whelan RL.Immunological advantages of advanced laparoscopy.Surg Clin North Am.2005:85:1-18.
77 Takagi K,Yamamori H,Morishima Y,et al.Preoperative immunosupp ression:its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy.Nutrition,2001,17:13-17.
78 Leaver HA,Craig SR,Yap PL,et al.Lymphocyte responses following open and minimally invasive thoracic surgery.Eur J Clin Invest,2000,30:230-238.
79 Hiraki S,Ono S,Kinoshita M,Interleukin-18 restores immune suppression in patients with nonseptic surgery,but not with sepsis.Am J Surg.2007;193:676-680.
80 Ajima K et,al Detection of T cell apoptosis after major operations.Eur J Surg 1999,165:1020-1023.
81 Ogawa K,Hirai M,Katsube T,et al.Suppression of cellular immunity by surgical stress.Surgery.2000;127:329-336.
82 彭聿平,邱一华.手术应激与免疫抑制生理科学进展2006,37:31-36.
83 Matsuda A,Furukawa K,Suzuki H,et al.Does impaired TH1/TH2 balance cause postoperative infectious complications in colorectal cancer surgery? J Surg Res.2007;139:15-21.
84 Budhu A,Forgues M,Ye QH,et al.Prediction of venous metastases,recurrence,and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.Cancer Cell.2006;10:99-111.
85 邢雪,吴在德.肝癌患者免疫功能的临床研究.中华实验外科杂志1996,13:333-334.
86 Hussein MR,Hassan HI,Hofny ER,et al.Alterations of mononuclear inflammatory cells,CD4/CD8+ T cells,interleukin lbeta,and tumour necrosis factor alpha in the bronchoalveolar lavage fluid,peripheral blood, and skin of patients with systemic sclerosis. J Clin Pathol. 2005:58:178-184.
87 Markowska J, Lacki JK, Jaroszewski J, et al.The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients. Eur J Gynaecol Oncol. 1995:16:54-58.
88 Ohara T, Takahashi M, Yamanaka H, et al.Serum lactate dehydrogenase and CD4+/CD8+ lymphocyte ratio predict survival in terminally ill cancer patients. Gan To Kagaku Ryoho. 2002:29:1779-1783.
89 Sevcikova L, Hundkovd L, Chorvdth B, et al.T-lymphocyte subsets (CD4/CD8 ratio) in breast cancer patients. Neoplasma. 1992:39:219-222.
90 Mascitelli L, Pezzetta F. Regulatory T cells, allergic diseases, and cancer. Chest. 2008 ;133:832.
91 Venet F, Chung CS, Monneret G, et al. Regulatory T cell populations in sepsis and trauma. J Leukoc Biol. 2008:83:523-535.
92 Peng L, Kjaergaard J, Plautz GE, et al. Tumor induced L-selectin high suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002:169:4811-4821.
93 Van Eden W, Wick G, Albani S, Cohen I. Stress, heat shock proteins, and autoimmunity: how immune responses to heat shock proteins are to be used for the control of chronic inflammatory diseases. Ann N Y Acad Sci 2007:1113:217-237.
94 Ni Choileain N, MacConmara M, Zang Y, et al. Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol. 2006:176:225-236.
95 Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005:115:3623-3633.
1 Sakaguchi S.Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses.Annu Rev Immunol 2004;22:531-562.
2 Emma J,Michaela DV,Denise G,et al.CD25 - regulatory Tcells and tumor immunity.Immunology Letters 2003;85:141-143.
3 Maloy K,Powrie F.Regulatory T cells in the control of immune pathology.Nature Immunol,2001,2:816.
4 Kubach J,Lutter P,Bopp T,et al.Human CD4+CD25+ regulatory T cells:proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function.Blood.2007;110:1550-1558.
5 Dieckmann D, Plottner H, Berchtold S Ex vivo isolation and characterization of CD4(+) CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001:193:1303-1310.
6 Goleva E, Cardona ID, Ou LS, et al. Factors that regulate naturally occurring T regulatory cell2mediated supp ression. J Allergy Clin Immunol, 2005, 116: 1094-1100.
7 Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003;171:6323-6327.
8 Jordan MS, Boesteanu A, Reed AJ et al: Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001:2:301-306.
9 Apostolou I, von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med. 2004:199:1401-1408.
10 Tarbell KV, Yamazaki S, Steinman RM. The interactions of dendritic cells with antigen-specific, regulatory T cells that suppress autoimmunity. Semin Immunol, 2006, 18: 93 - 102.
11 Bacchetta R, Gregori S, RoncaroloMG. CD4 + regulatory Tcells: mechanisms of induction and effector function. Autoimmun Rev, 2005, 4: 491-496.
12 Mahnke K, Enk AH. Dendritic cells: key cells for the induction of regulatory T cells? Curr Top Microbiol Immunol, 2005, 293: 133-150.
13 Nelson BH: IL-2, regulatory T cells, and tolerance. J Immunol. 2004 ,172:3983-3988.
14 Takahashi T, Tagami T, Yamazaki S et al. Immunologic self -tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte- associated antigen 4. J Exp Med. 2000:192:303-310.
15 Ronchetti S, Zollo O, Bruscoli S, et al. Frontline: GITR, a member of the TNF receptor superfamily, is co-stimulatory to mouse T lymphocyte subpopulations. Eur J Immunol, 2004,34:613-622.
16 Zheng SG, MengLZ, Wang JH, et al. Transfer of regulatoryT cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4 + CD25 + cells in the recip ient. Int Immunol, 2006, 18: 279-289.
17 Becker C, FantiniMC, NeurathMF. TGF-beta as a T cellregulator in colitis and colon cancer. Cytokine Growth FactorRev, 2006, 17: 97 - 106.
18 Schramm C, Huber S, Protschka M, et al. TGF- β regulates the CD4 + CD25 + T cell pool and the exp ression of Foxp3 in vivo. Int Immunol, 2004, 16: 1241-1249.
19 Fontenot JD, GavinMA, Rudensky A Y. Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells. Nat Immunol, 2003; 4: 330 - 336.
20 Khattri R, Cox T, Yasayko S, et a l. An essential role for Scurfin in CD4 + CD25 + T regulatory cells. Nat Immunol, 2003; 4: 337 -342.
21 Yagi H, N omura T, N akamura K, et a 1. C rucial role of FOXP3 in the development and function of human CD25 + CD4 + regulatory T cells. Int Immunol, 2004; 16: 1643 - 1656.
22 RoncaroloMG, L evings M K. The role of different subsets of T regulatory cells in controlling autoimmunity. Curr Opin Immunol, 2000; 12: 676 - 683.
23 Lan YY, Wang Z, Raimondi G, et al. Alternatively activateddendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol. 2006;177:5868-5877.
24 Coffer PJ , Burgering BM. Forkhead box transcrip tion factors and their role in the immune system. Nat Rev Immunol, 2004, 4: 889-899.
25 FantiniMC, Becker C, Monteleone C, et al. TGF-beta induces a regulatory phenotype in CD4 + CD25 + T cellsthrough Foxp3 induction and down-regulation of Smad7. JImmunol, 2004, 172: 5149-5153.
26 Gelman AE et al Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol. 2004;172:6065-6073.
27 Caramalho, I. et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J. Exp Med. 2003, 197: 403-411.
28 Peng G. Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science. 2005; 26:1380-1384.
29 YipingYang et al Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nature immunology 2004,5:508-515.
30 Shevach E M. CD4 + CD25 + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2: 389-400.
31 LevingsM K, Bacchetta R, Schulz U et al. The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. Int Arch Allergy Immunol 2002; 129: 263-276.
32 Misra N, Bayry J, Lacroix Desmazes S, et al. Cutting edge: human CD4 + CD25 + T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172 : 4676-4680.
33 Stassen M, Schmitt E, Jonuleit H. Human CD4 + CD25+regulatory T cells and infectious tolerance. Transp lantation 2004, 77: S23-25.
34 akaguchi S. The origin of F0XP3-expressing CD4+ regulatory T cells:thymus or periphery. J Clin Invest. 2003 112:1310-1312.
35 Cederbom L, Hall H, Ivars F: CD4+CD25+ regulatory T cells down-regulatecostimulatory molecules on antigen- presenting cells. Eur J Immunol. 2000;30:1538-1543.
36 Fantini MC, Becker C, Tubbe I, et al. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut. 2006,55:671-680.
37 Huang X, Zhu J, Yang Y. Protection against autoimmunity in nonlymphopenic hosts by CD4+ CD25+ regulatory T cells is antigen-specific and requires IL-10 and TGF-beta. J Immunol. 2005 ,175:4283-4291.
38 Zwar TD, Read S, van Driel IR, et al. CD4 + CD25 + regulatory T cells inhibit the antigen-dependent expansion of self-reactive T cells in vivo. J Immunol 2006, 176: 1609-1617.
39 Barthlott T, Kassiotis G, StockingerB. T cell regulation as aside effect of homeostasis and competition. J Exp Med 2003, 197: 451-460.
40 Larmonier N, Marron M, Zeng Y, Tumor-derived CD4(+)CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother. 2007;56:48-59.
1 陈慰峰主编.医学免疫学.第四版.北京:人民卫生出版社,2004,226-227.
2 Shevde LA,et,al.Studies on functional status of circulating lymphocytes in unaffected members from cancer families.Human Immunol 1998;59:373-381.
3 Reuben JM,Hersh EM.Delayed hypersensitivity responses of cancer patients to recall antigens using a new multitest applicator.Ann Allergy 1984;53:390-394.
4 Almand B Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001:166:678-689.
5. Tomer, Y., et, al. Autoantibodies, autoimmunity and cancer. Oncol. Rep. 1998, 5: 753-761
6 Finch, C. E., Crimmins, E. M. Inflammatory exposure and historical changes in human life-spans. Science 2004, 305: 1736-1739.
7 Dannenberg, A. & Subbaramaiah. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell, 2003, 4: 431-436.
8 Enzler, T. et al. Deficiencies of GM-CSF and interferon link inflammation and cancer. J. Exp. Med. 2003, 197: 1213 - 1219.
9. Hoebe, K., Janssen, E. & Beutler, B. The interfacebetween innate and adaptive immunity. Nature Immunol. 2004, 5: 971-974.
10. Firestein, G. S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423: 356-361.
11. Schmielau, J et, al. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 2001, 61: 4756-4760.
12 Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer 2005, 5,: 263 - 274.
13 Balkwill, F, et, al. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 2005, 7: 211 -217.
14 Esposito, I. et al. Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma. J. Clin. Pathol. 2004,57:630-636.
15 Egeblad, M. &Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nature Rev. Cancer 2002,2:161-174.
16 Zha, S., et, al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004,215: 1-20.
17 Pikarsky, E. et al. NF- B functions as a tumour promoter in inflammation - associated cancer. Nature 2004, 431: 461-466 .
18 Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.Nature Med.2004,10:942-994.
19 Rosenberg,S.A.,et,al.Cancer immunotherapy:moving beyond current vaccines.Nature Med.2004,10:909-915.
20 Smytb,M.J.et,al.NKT cells and tumor immunity-a double-edged sword.Nature Immunol.2000,1:459-460.
21 Firestein,G.S.Evolving concepts of rheumatoid arthritis.Nature 2003,423:356-361.
22 Hoebe,K.,et,al.The interface between innate and adaptive immunity.Nature Immunol.2004,5:971-974.
23 Tan,E.M.et,al.Relative paradigms betweenautoantibodies in lupus and autoantibodies in cancer.Clin.Exp.Immunol.2003,134:169-177.
24 De Visser,K.E.,Korets,L.V.& Coussens,L.M.De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.Cancer Cell 2005,7:411-423.
25 Mueller,M.M.,Fusenig,N.E.Friends or foes-bipolar effects of the tumor stroma in cancer.Nat.Rev.Cancer,2004;4:839-849.
26 Pollard,J.W.Tumor-educated macrophages promote tumor progression and metasta-sis.Nat.Rev.Cancer 2004;4:71-78.
27 Budhu,A.,et,al.Predictionof venous metastases,recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.Cancer Cell 2006,10:99-111.
28 Duan XZ,et,al Decreased frequency and function of circulating plasmocytoid dendritic cells(pDC) in hepatitis B virus infected humans.J Clin Immunol.2004;24:637-646
29 Wang FS,et,al Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infectionWorld J Gastroenterol.2001;7:537-541.
30 Genel F,et,al.Decreased ratio of CD4/CD8 lymphocytes might be predictive for successful interferon alpha and lamivudine combined therapy in childhood chronic hepatitis B infection:A preliminary studyJ Gastroenterol Hepatol.2003;18:645-650.
31 何东苟,陈柏铭,林勇平.病毒性肝炎患者两类免疫效应细胞的功能变化临床肝胆病杂志2000,16:30-31.
32 Stoop JN,et,al Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection.Hepatology.2005;;41;:771-778.
33 Falasca K,et,al.Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C Ann Clin Lab Sci.2006;36:144-50
34 杨朝晖,高峰,张培会等.重型肝炎内毒素与细胞因子及细胞免疫的相关性实用医药杂志2006,23:516-19.
35 Ayada M,et,al.Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection.Hepatol Res.2006;34:214-221.
36 Yu,F.L.,et,al.Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3.J.Hepatol,2005,42:520 - 527.
37 Song,l.H.,et,al.Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus.J.Clin.Virol.2003;28:93-103.
38 Carretero,M.,et,al.The hepatitis B virus X protein binds to and activates the NH(2)-terminal trans-activation domain of nuclear factor of activated T cells-1.Virology,2002,299:288-300.
39 Akpolat N,et,al Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B.World J Gastroenterol.2005;11:3260-3263.
40 李嘉,朱理珉,梁树人等.乙型肝炎病毒核心区基因变异与细胞免疫中华肝脏病杂志2003,11:533-535.
41 王静艳,穆桂玲,刘沛等.乙型重型肝炎基因变异与免疫异常的关系中华传染病杂志2001,19:73-76.
42 冯志杰,任锡玲,牛然明.肝炎后肝硬变肝损害与细胞免疫功能新消化病学杂志1997:5:88-89.
43 Bahr MJ,Function of the immune system in liver cirrhosis Z Gastroenterol.2001;39:601-607.
44 Attallah AM,et,al.Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.Clin Exp Med.2003;3:181-185.
45 Morita K,et,al.Peripheral lymphocyte subsets vary with stage of hepatitis C virus-associated liver disease.Hepatogastroenterology.2005;52:1803-1808.
46 黄团新,周永兴,韩秀珍.肝炎肝硬化及原发性肝癌患者外周血T淋巴细胞亚群分析临床内科杂志,2001,18:69-70
47 伍艳玲,綦盛麟,石铭.肝硬化病人外周血T淋巴细胞亚群及HBV-DNA含量的变化分析大连医科大学学报2005,27:301-302.
48 Akbar,S.M.,et,al.Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis;relevance to pathogenesis.Cancer heft.2001,171:125-132.
49 Kim,Y.J.,et,al.Association of transforming growthfactor-1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.Exp.Mol.Med.2003,35:196-202.
50 周伏喜,卢放根,伍汉文等.急性肝炎、肝硬化患者血清一氧化氮与免疫细胞因子的关系湖南医科大学学报1999,24:379-380.
51 Masini E,et,al Changes in the production of nitric oxide and superoxide by inflammatory cells in liver cirrhosisInt.Arch Allergy Immunol.1995107:197-198.
52 Giron-Gonzalez JA,et,al Implication of inflammation-related cytokines in the natural history of liver cirrhosishiver Int.2004;24:437-445.
53 Giron-GonzalezJA,et,al Adhesion molecules as a prognostic marker of liver cirrhosis。Scand J Gastroenterol.2005;40:217-224.
54 Lin SY,et,al Increased serum leptin concentrations correlate with soluble tumour necrosis factor receptor levels in patients with cirrhosis.Clin Endocrinol.2002,57:805-811.
55 Nakamoto,Y.,Guidotti,L.G.,Kuhlen,C.V.,Fowler,P.,Chisari,F.V.Immune pathogenesis of hepatocellular carcinoma.J.Exp.Med.1998,188:341-350.
56 Nakamura,I.,Imawari,M.Cellular immune response in HCV infection.J.G -astroenterol.2000,35:881-889.
57 Rehermann,B.Immune responses in hepatitis B virus infection.Semin.Liver Dis.2003,23:21-38
58 Soresi Met al Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.World J Gastroenterol.2006,12:2563-2568.
59 Yuen,M.F.,et,al.Transforming growth factor-_1,activin and follistatin in patientswith hepatocellular carcinoma and patients with alcoholic cirrhosis.Scand.J.Gastroenterol.2002,37:233-238.
60 Hu,R.H.,et,al.Secretion of acute-phase proteins before and after hepatocellular carcinoma resection.J.Formos.Med.Assoc.1999,98:85-91.
61 Tangki jvanich,et,al.Serum interleukin-6 and interferon levels in patients with hepatitis B-associated chronic liver disease.Asian Pac.J.Allergy Immunol.2000,18:109- 114.
62 Hattori E,et,al.Possible contribution of circulating interleukin-10(IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma.Hepatol Res.2003;27(4):309-314.
63 Okumoto K,et,al.Possible contribution of circulating transforming growth factor-betal to immunity and prognosis in unresectable hepatocellular carcinoma.Liver Int.2004;24:21-28.
64 Chen S,et al.Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma:relevance to hepato- carcinogenesis.Cancer Lett.2000;148:49-57.
65 Grolleau A,et,al.Dendritic cell-based vaccines for cancer therapy.Cancer Treat Res.2005;123:181-205
66 Lars A,et,al.Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.Cancer research 2005,65:2457-2464.
67 Maecker HL,Yun Z,Maecker HT,et al.Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.Cancer Cell.2002;2:139-148.
68 Hahne M,Rimoldi D,Schroter P,et al.Melanoma cell expression of Fas ligand:implications for tumor immune escape.Science 1996,274:1363-1366.
69 张建国,徐高四,李伟等.肝癌细胞Fas-FasL途径反击免疫细胞.细胞生物学杂志2008,30:100-104.
70 Yuen MF,et,al.Expression of Fas antigen(CD95) in peripheral blood lymphocytes and in liver-infiltrating,cytotoxic lymphocytes in patients with hepatocellular carcinoma.Cancer.2001;92:2136-2141.
71 Tang TJ Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol. 2006:37:332-338
72 Yin XY, et, al. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology. 2003:50:1281-1284.
73 Cai XY et , al Dendritic cell infiltration and prognosis of human hepatocellular carcinomaJ Cancer Res Clin Oncol. 2006:132:293-301
74 Unitt E, et, al. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 2005:41:722-730.
75 Xiu Hua Yang et, al. Increase of CD4+CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma. Journal of Hepatology 2006, 45:254-262.
76 Unitt E, et,al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006:45:246-253.
77 Yuen MF, et, al Expression of inhibitory receptors in natural killer (CD3(-)CD56(+)) cells and CD3(+)CD56(+) cells in the peripheral blood lymphocytes and tumor infil -trating lymphocytes in patients with primary hepatocellular carcinoma. Clin Immunol. 2001:101:264-269.
78 Ponte, M, et, al. Cytokine induced expression of killer inhibitory receptors in human T lymphocytes. Eur. Cytokine Netw. 1998, 9: 69 - 72,
79 Kakumu, S et, al, Serum levels ofIL-10, IL-15 and soluble tumor necrosis factor-a (TNF-a) receptors in type C chronic liver disease. Clin. Exp. Immunol. 1997, 109: 458-463,.
80 Iwamoto A, et, al. Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumori. 2006 ; 92:130-3
81 Ikeguchi M, et, al Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas.. Onkologie. 2005 ; 28:255-9.
82 Anuradha Budhu, et, al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 2006 ; 10; :99-111.
83 Heneghan, M. A., et, al. Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int. J. Gastrointest. Cancer 2003, 34: 19-26.
84 Kroeger, K. M., Carville, K. S., Abraham, L. J. The -308 tumor necrosis factor-promoter polymorphism effects transcription. Mol. Immunol. 1997, 34, 391-399.
85 Hirankarn, N., et, al. Interleukin-1 gene polymorphism associated with hepa- tocellular carcinoma in hepatitis B virus infection. World J. Gastroenterol. 2006, 12: 776-779.
86 Cornell RP etal. Acute phase response after acute liver injury by partial hepatectomy in rats as indicators of cytokine release Hepatology 1990,11:923-931.
87 Milland J et al Gene expressioin in regeneratin and acute-phase rat liver . Am J Physiol , 1990, 259: 340-347
88 Gupta A et, al Effect of laparoscopy on immune function. Br J Surg 2001,88:1296-1306
89 From Bical OM etal Comparison of the inflammatory response between miniaturized and standard CPB circuits in aortic valve surgery. Eur J Cardiothorac Surg. 2006:29:699-702
90 Burpee SE et al The metabolic and immune response to laparoscopic vs open liver resection. Surg Endosc 2002, 16:899-904
91 Schietroma M et, al changes in the blood coagulation, fibrinolysis, and cytokine profile during laparoscopic and open cholecystectomy. Surg Endosc, 2004, 18:1090-1096
92 Halevy A et al Comparison of the serum C-reactive protein concentration for laparoscopic versus open cholecystectomy. Surg Endosc, 1995,9:280-282
93 Kaminska et al CRP, TNF , IL-1ra, IL-6, IL-8 and IL-10 in Blood Serum of Colorectal Cancer Patients Pathology Oncology Research 2000, 6: 38-41
94 Hu X et al Evaluation of the minimal invasiveness of laparoscopic operation for colorectal carcinoma Zhonghua Wei Chang Wai Ke Za Zhi. 2005 , 8:404-6
95 Weber DM Laparoscopic surgery:an excellent approach in elderly patients. Arch Surg 2003,138:1083-1088
96 Lacy AM et, al Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomized trial. Lancet 2002,359:2224-2229.
97 VittimbergaFJ et al Laparoscopic surgery and the systemic immune response. Ann surg 1998,227:326-324
98 Weitz J, et, al Surgical stress and minimal residual disease detection. Semin Surg Oncol 2001,20:329-333
99 Holmgren L , et , al Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995,1:149-153
100 Li TS, et, al The influence of tumour resection on angiostatin levels and tumour growth-an experimental study in tumour-bearing mice. European J of cancer 2001,37:2283-2288
101 Hofer SO, et, al the effect of surgical wounding on tumor development. Eur J Surg Oncol 1999,25:231-243.
102 Takagi K, Yamamori H, Morishima Y, et al. Preoperative immunosupp ression: its relationship with high morbidity and mortality in patients receiving thoracic esophagectomy. Nutrition, 2001, 17: 13 - 17.
103 Leaver HA, Craig SR, Yap PL, et al. Lymphocyte responses following open and minimally invasive thoracic surgery. Eur J Clin Invest, 2000, 30: 230-238.
104 Ajima K et, al Detection of T cell apoptosis after major operations. Eur J Surg 1999,165:1020-1023.
105 Ogawa K, Hirai M, Katsube T, et al. Suppression of cellular immunity by surgical stress. Surgery 2000,127:329-336.
106 彭聿平,邱一华．手术应激与免疫抑制．生理科学进展 2006,37：31-36．
107 Atanackovic D et, al Acute psychological stress alerts the adaptive immune response: Stress-induced mobilization of effector T cells. J Neuroimmunol. 2006:176:141-52
108 Atanackovic D et, al Patients with solid tumors treated with high-temperature whole body hyperthermia show a redistribution of naive/memory T-cell subtypes Am J Physiol Regul Integr Comp Physiol. 2006 , 290:585-594
109 邢雪,吴在德．肝癌患者免疫功能的临床研究．中华实验外科杂志、．1996,13：333-334．
110 Itoh, Y., et, al. Hepatic damage induced by transcatheter arterial chemoembolization elevates serum concentrations of macrophage-colony stimulating factor. Liver, 1999 19: 97 - 103.
111 Hironori Kaneko, et al Laparoscopic liver resection of hepatocellular carcinoma. The American Journal of Surgery 2005,189 :190 -194
112 Ishikawa M et, al Clarification of risk factors for hepatectomy in patients with hepatocellular carcinoma Hepatogastroenterology. 2002, ;49:1625-31.
113 Chijiiwa K Serum interleukin-6 and hepatocyte growth factor levels in patients after hepatectomy. Hepatogastroenterology. 2002 , 49:467-471.
114 Kimura F, Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection J Surg Res. 2006, 133:102-112.
115 Sato, T., et , al. Changes in tumor necrosis factor-a and interleukin-1beta production following liver surgery on cirrhotic patients. Hepatogastroenterology 1996,43: 1148-1153.
116 Calvin SH et, al Is minimal access surgery for cancer associated with immunologic benefits? World J Surg 2005, 29: 975-981.
117 Reichner, J. S., et, al. Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann. Surg. Oncol. 1998, 5: 279-286.
118 Wagner, K., et, al. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology, 2004,126: 1828-1843.
119 Kubo F, et, al. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol. 2005:12:800-807
120 Hira, E., et, al. Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radicalresection for hepatocellular carcinoma. Cancer 2005 , 103 : 588 - 598.
121 Wang, L ,et, al. Mechanism of interferon_ on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice. J. Gastrointest. Surg. 2003, 7: 587 - 594.
122 Nagao, M., et, al. The impact of interferon _ receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology, 2000 32: 491 - 500.
123 Akiba, J., et, al. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int. J. Oncol. 2001, 18, 257-264.
124 Asakawa M, et, al. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer. 2006:118:564-570
125 Gelman AE et al Toll-like receptor ligands directly promote activated CD4+ T cell survival J Immunol. 2004;172:6065-6073
126 Peng G Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function Science. 2005 , 26 ;309:1380-1384
127 YipingYang et al Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nature immunology 2004,5:508-515
128 Cerwenka A et al NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer Tissue Antigens. 2003 , 61:335-343
129 Holdenrieder S. Soluble MICA in malignant diseases. Int J Cancer. 2006, 118:684-687
130Liyanage UK, et al. Prevalence of regulatory T-cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-2761.
131 Curiel TJ, et al. Specific recruitment of regulatory T-cells in ovarian carcinoma fosters im -mune privilege and predicts reduced survival. Nat Med 2004;10:942 - 9.
132 Viguier M, et al. Foxp3 expressing CD4(+) CD25(high) regulatory T cells are over represent -ed in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
133 Wang RF. Functional control of regulatory T cells and cancer immunotherapy Semin Cancer Biol. 2006 16:106-114
134 Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004:22:531-562.
135 Wang RF Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer. Semin Cancer Biol. 2006, 16:73-79.
136 Wang HY, et al . Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T-cells. J Immunol 2005 ; 174:2661-2670.
137 Chen W, et al. Conversion of peripheral CD4+ CD 25- naive T-cells to CD4+CD25+ regulatory T-cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198:1875 - 1886.
138 Apostolou I, et al In vivo instruction of suppressor commitment in naive T-cells. J Exp Med 2004;199:1401 - 1408.
139 Paul A. Antony, et, al. Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. J Immunol. 2006; 176: 5255-5266.
140 Fontenot JD, et, al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 200 5;6:1142 - 1151.
141 Kreher C R , Dittrich M T , et al. CD4 + and CD8 + cells in cryopreserved human PBMC maintain full functionality in cytokine EL ISPOT assays . Journal of Immunological Methods , 2003 ,278 :79-93.